Multigene-engineered fibroblast-derived biomimetic vesicles for cancer multimodal targeting and immune reprogramming

Despite advances of biomimetic vesicles in cancer therapy, clinical challenges such as biosafety, scalability, and therapeutic efficacy remain significant hurdles. To address these limitations, we reveal the critical tumor-homing motifs of cancer cell membrane vesicles: a synergistic "chemotactic recruitment-adhesion anchoring" cascade effect, especially chemokine axes (e.g., CXCL12/CXCR4) and integrins (e.g., αVβ3). In this study, we identify autologous fibroblasts as an ideal "chassis" cell for engineering biomimetic carriers. Using this platform, we construct multigene-engineered fibroblast-derived nanovesicles (X-Fb-MNVs) coexpressing critical chemokine receptor CXCR4 and adhesion ligand iRGD, as well as PD-1 and CD47 protein, which achieved robust and broad-spectrum tumor targeting across breast, liver, pancreatic, and colon cancer PDX models. Significantly, CD47-modified X-Fb-MNVs reduced hepatic accumulation and phagocytic clearance, thereby minimizing off-target effects in vivo and improving tumor targeting efficiency. By loading diABZI STING agonist into X-Fb-MNVs with overexpressed PD-1, our system activates both T cell and innate immunity, reversing ICB resistance and achieving 83.3% survival with no tumor recurrence and long-term immune surveillance over 90 d, whereas no mice survived with free diABZI treatment. By merging multimodal targeting, immune reprogramming, and scalable production into a single platform, X-Fb-MNVs represent a remarkable biomimetic system with transformative potential for a wide-spectrum cancer immunotherapy.

Authors

Institutions

Publication Details

Journal
Proceedings of the National Academy of Sciences
Published
2026-11-17
DOI
https://doi.org/10.1073/pnas.2619464123
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Multigene-engineered fibroblast-derived biomimetic vesicles for cancer multimodal targeting and immune reprogramming

Yunzhi Liu, Yanan Tan, Anne W.M. Lee, Baifeng Zhang et al.
6 links
Proceedings of the National Academy of Sciences
Nanoparticle-Based Drug Delivery
article

Multigene-engineered fibroblast-derived biomimetic vesicles for cancer multimodal targeting and immune reprogramming

Yunzhi Liu, Yanan Tan, Anne W.M. Lee, Baifeng Zhang, Xin‐Yuan Guan, Lu Bai, Zhihao Xing, Lifen Zhang, Shanshan Li, Ziyang Qi, Zuhua Wang, Quan Wan, Min Luo, LanQi Gong, ZhiTong Bing, Lei Yang
article en

Abstract

Despite advances of biomimetic vesicles in cancer therapy, clinical challenges such as biosafety, scalability, and therapeutic efficacy remain significant hurdles. To address these limitations, we reveal the critical tumor-homing motifs of cancer cell membrane vesicles: a synergistic "chemotactic recruitment-adhesion anchoring" cascade effect, especially chemokine axes (e.g., CXCL12/CXCR4) and integrins (e.g., αVβ3). In this study, we identify autologous fibroblasts as an ideal "chassis" cell for engineering biomimetic carriers. Using this platform, we construct multigene-engineered fibroblast-derived nanovesicles (X-Fb-MNVs) coexpressing critical chemokine receptor CXCR4 and adhesion ligand iRGD, as well as PD-1 and CD47 protein, which achieved robust and broad-spectrum tumor targeting across breast, liver, pancreatic, and colon cancer PDX models. Significantly, CD47-modified X-Fb-MNVs reduced hepatic accumulation and phagocytic clearance, thereby minimizing off-target effects in vivo and improving tumor targeting efficiency. By loading diABZI STING agonist into X-Fb-MNVs with overexpressed PD-1, our system activates both T cell and innate immunity, reversing ICB resistance and achieving 83.3% survival with no tumor recurrence and long-term immune surveillance over 90 d, whereas no mice survived with free diABZI treatment. By merging multimodal targeting, immune reprogramming, and scalable production into a single platform, X-Fb-MNVs represent a remarkable biomimetic system with transformative potential for a wide-spectrum cancer immunotherapy.

Proceedings of the National Academy of SciencesVol. 123(47)
Chinese Academy of Sciences (CN), Institute of Modern Physics (CN), University of Hong Kong - Shenzhen Hospital (CN), Shenzhen University Health Science Center (CN), Shenzhen Children's Hospital (CN), Southern Medical University (CN), University of Hong Kong (HK)
National Natural Science Foundation of China, Sanming Project of Medicine in Shenzhen, Shenzhen Science and Technology Innovation Program
Good health and well-being
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon